Atrium Therapeutics, Inc. (RNA) on Thursday said it earned a $15 million milestone payment from Bristol Myers Squibb Co. (BMY) after successfully delivering a development candidate for a cardiology-targeted compound under their collaboration.
The payment is part of a global licensing and research agreement focused on RNA-based therapies for cardiovascular diseases.
Under the deal, Atrium could receive up to about $1.35 billion in research and development milestone payments and up to $825 million in commercial milestone payments, along with tiered royalties on net sales. Bristol Myers Squibb will fund future clinical development, regulatory and commercialization activities under the partnership.
"This milestone marks a meaningful step forward for Atrium, further expanding our RNA delivery platform and our ability to generate high quality cardiology development candidates," said Kathleen Gallagher, President and Chief Executive Officer of Atrium Therapeutics.
Atrium shares closed at $13.66 on Wednesday, up 0.96%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.